Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGAV | P06756 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7675733 | 0.91 | DRD2 (0.47) | DRD2ADRA1ADRD3ITGB3ITGAV | |
| SCHEMBL2833670 | 0.84 | KDM4E (0.42) | DRD2ADRA1ADRD3TP53HRH2 | |
| SCHEMBL2833676 | 0.84 | KDM4E (0.42) | DRD2ADRA1ADRD3TP53HRH2 | |
| SCHEMBL2843026 | 0.76 | DRD3 (0.56) | DRD2ADRA1ADRD3ITGB3ITGAV | |
| SCHEMBL7675724 | 0.74 | DRD2 (0.49) | DRD2ADRA1ADRD3ITGB3ITGAV | |
| SCHEMBL2833666 | 0.72 | KDM4E (0.49) | DRD2ADRA1ADRD3ITGB3ITGAV | |
| Trifluoroacetic Acid SCHEMBL5856786 | 0.71 | DRD2 (0.53) | DRD2ADRA1ADRD3ITGB3ITGAV | |
| SCHEMBL13118499 | 0.70 | DRD2 (0.61) | DRD2ADRA1ADRD3 | |
| SCHEMBL12973188 | 0.69 | DRD2 (0.60) | DRD2ADRA1ADRD3 | |
| SCHEMBL5856769 | 0.68 | ALDH1A1 (0.57) | DRD2ADRA1ADRD3ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | ITGA5, ITGA2B, ITGAV | DRD2 1646/4885ADRA1A 192/4885DRD3 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.